24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
ACALIEVA 100 MG is an Capsule medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | ACALIEVA 100 MG |
|---|---|
| Composition | Acalabrutinib Capsules 100mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsule |
| Packaging | Btl (30 cap) |
| Country of Origin | India |
Acalabrutinib Capsules 100 mg (Acalabrutinib Capsules 100mg) is a widely used Capsule medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
ACALIEVA 100MG (Acalabrutinib Capsules 100mg) is a targeted anticancer medicine used in the treatment of certain blood cancers and lymphatic system cancers. It contains Acalabrutinib, a highly effective Bruton's Tyrosine Kinase (BTK) inhibitor that helps slow down the growth and spread of abnormal cancer cells in the body. This medicine is commonly prescribed by oncologists and hematology specialists as part of advanced cancer treatment protocols for chronic blood-related malignancies.
Acalabrutinib works by blocking the activity of BTK proteins that are involved in the growth and survival of cancerous B-cells. By interrupting these cancer cell signaling pathways, ACALIEVA 100MG helps reduce the multiplication and survival of abnormal cells, supporting long-term cancer management and disease control.
This targeted therapy medicine is widely used in modern hematology-oncology treatment because of its precision-based mechanism and effectiveness in managing blood cancers with fewer effects on healthy cells compared to some traditional chemotherapy medicines.
ACALIEVA 100MG is mainly prescribed for the treatment of:
• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Certain relapsed or refractory blood cancers
• Advanced hematology-oncology treatment programs
Doctors may prescribe Acalabrutinib Capsules alone or in combination with other anticancer medicines depending on the patient’s condition, stage of disease, previous treatment history, and response to therapy.
Blood cancers can affect the immune system, bone marrow, lymph nodes, and overall health. Targeted therapy medicines like Acalabrutinib help control cancer progression by specifically targeting cancer-related proteins responsible for abnormal B-cell growth.
ACALIEVA 100MG is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and reliable therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hematology treatment.
Patients undergoing treatment with ACALIEVA may require regular blood tests, medical monitoring, infection screening, and overall health assessments during therapy. Proper monitoring helps improve treatment effectiveness and reduce the risk of complications or serious side effects.
Due to its effectiveness in targeted cancer therapy and hematology care, ACALIEVA 100MG has become an important medicine in modern oncology treatment protocols and long-term blood cancer management programs.
ACALIEVA 100MG (Acalabrutinib Capsules 100mg) is mainly used for the treatment and management of blood cancers and lymphatic system disorders.
ACALIEVA is widely used in the treatment of chronic lymphocytic leukemia, a type of cancer affecting white blood cells.
Doctors may prescribe Acalabrutinib Capsules for patients with small lymphocytic lymphoma affecting the lymphatic system.
The medicine is commonly used in patients with mantle cell lymphoma who require advanced targeted therapy.
ACALIEVA may be prescribed for patients whose cancer has returned or does not respond adequately to previous treatment.
The medicine is included in advanced hematology-oncology protocols for long-term disease management and supportive cancer care.
Acalabrutinib helps slow down abnormal B-cell growth and supports targeted cancer treatment effectiveness.
Acalabrutinib belongs to a class of medicines known as Bruton’s Tyrosine Kinase (BTK) inhibitors.
ACALIEVA works by:
• Blocking BTK protein activity
• Interrupting cancer cell signaling pathways
• Reducing abnormal B-cell survival
• Slowing cancer progression
• Helping destroy cancer cells naturally
This targeted mechanism helps oncologists manage blood cancers more effectively.
Like other anticancer medicines, ACALIEVA 100MG may cause side effects in some patients. Side effects may vary depending on the patient’s health condition, treatment duration, and response to therapy.
Mild to moderate headaches may occur during treatment.
Patients may experience tiredness, weakness, or low energy levels.
Digestive discomfort or loose stools may develop during therapy.
Some patients may experience body pain, muscle aches, or joint discomfort.
The medicine may increase the risk of minor bruising or bleeding.
Patients may occasionally develop fever or infection-related symptoms.
Mild nausea or stomach discomfort may occur.
Some individuals may become more vulnerable to infections during treatment.
Skin irritation or mild rash may develop in certain patients.
Certain serious side effects may require immediate medical attention.
• Severe bleeding
• Chest pain
• Difficulty breathing
• Severe allergic reactions
• Irregular heartbeat
• Persistent fever
• Signs of severe infection
• Severe dizziness or fainting
Patients should immediately consult their healthcare provider if serious symptoms occur during treatment.
The dosage of ACALIEVA 100MG (Acalabrutinib Capsules 100mg) should always be determined by a qualified healthcare professional based on the patient’s medical condition and treatment plan.
Different hematological conditions may require different treatment schedules.
The patient’s age, health status, and treatment tolerance influence dosage planning.
Earlier chemotherapy or targeted therapy may affect dosage decisions.
Patients with liver-related conditions may require careful monitoring and dosage adjustment.
Doctors may adjust dosage depending on treatment effectiveness and side effects.
• Take the capsule exactly as prescribed
• Swallow the capsule whole with water
• Do not crush, chew, or open the capsule
• Take the medicine at the same time daily
• Follow the prescribed treatment schedule carefully
• Do not stop treatment without medical advice
Regular blood monitoring and medical supervision may be necessary during therapy.
Before starting treatment, patients should inform their doctor if they have:
• Heart disease
• Liver disorders
• Bleeding disorders
• Active infections
• High blood pressure
• Previous cancer treatment complications
Patients should also discuss all ongoing medicines and supplements because certain medicines may interact with Acalabrutinib.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
• Store in a cool and dry place
• Protect from direct sunlight and moisture
• Keep out of reach of children
• Store at recommended room temperature
• Advanced targeted cancer therapy
• Trusted hematology-oncology treatment support
• Effective BTK inhibitor formulation
• Reliable blood cancer management medicine
• Manufactured under strict pharmaceutical standards
• Suitable for modern oncology treatment protocols
It is mainly used for the treatment of blood cancers such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma.
Acalabrutinib is a targeted anticancer medicine known as a BTK inhibitor used in hematology-oncology treatment.
It is considered a targeted therapy medicine rather than traditional chemotherapy.
Yes, some patients may experience bruising or bleeding-related side effects during treatment.
Yes, doctors usually recommend blood tests and regular medical monitoring during therapy.
No, patients should never stop treatment without consulting their healthcare provider.
Yes, this medicine should always be used under the supervision of qualified healthcare professionals.
Yes, the medicine helps slow abnormal cancer cell growth and supports long-term disease management.